Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16818241 | 1.00 | GPR119 (0.55) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL16818344 | 1.00 | GPR119 (0.55) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL17475590 | 0.94 | GPR119 (0.50) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL17475591 | 0.94 | GPR119 (0.50) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL15566031 | 0.88 | GPR119 (0.55) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL18249606 | 0.88 | HDAC1 (0.45) | GPR119DPP4SMN1; SMN2MMP13GPR6 | |
| SCHEMBL28829714 | 0.83 | GPR6 (0.46) | GPR6 | |
| SCHEMBL5182367 | 0.81 | GPR119 (0.57) | GPR119DPP4SMN1; SMN2MMP13MEN1 | |
| SCHEMBL16818164 | 0.81 | GPR6 (0.48) | GPR6 | |
| SCHEMBL18249647 | 0.80 | HDAC1 (0.39) | GPR119DPP4SMN1; SMN2MMP13MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105230-B1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| EP-3453709-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | Taketa Pharmaceutical Company Limited (JP) | 2019-01-15 | — | — | US | disclosed |
| US-20180346464-A1 | SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2018-12-06 | — | — | US | disclosed |
| EP-3105216-B1 | PYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-10 | — | — | EP | disclosed |
| EP-3083620-B1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-03 | — | — | EP | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160031881-A1 | TETRAHYDROPYRIDOPYRAZINES AS MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9181249-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| WO-2015123533-A1 | PYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| WO-2015123505-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015095728-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175602-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175602-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR119 16/4885DPP4 1481/4885SMN1; SMN2 3875/4885 |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR119 25/4885DPP4 2675/4885SMN1; SMN2 2970/4885 |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR119 17/4885DPP4 1252/4885SMN1; SMN2 3800/4885 |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR119 17/4885DPP4 1252/4885SMN1; SMN2 3800/4885 |
| US-20160031881-A1 | TETRAHYDROPYRIDOPYRAZINES AS MODULATORS OF GPR6 | GPR6, GPR65, GPR52 | GPR119 17/4885DPP4 1252/4885SMN1; SMN2 3800/4885 |
| US-20180346464-A1 | SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS | GPR6, GPR65, GPR55 | GPR119 12/4885DPP4 1031/4885SMN1; SMN2 4167/4885 |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR119 16/4885DPP4 1481/4885SMN1; SMN2 3875/4885 |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR119 11/4885DPP4 1407/4885SMN1; SMN2 4508/4885 |
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | GPR6, GPR65, GPR55 | GPR119 12/4885DPP4 1031/4885SMN1; SMN2 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.